Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

MLA

Henry, N.Lynn, et al. “Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 30, no. 9, Mar. 2012, pp. 936–42. EBSCOhost, https://doi.org/10.1200/JCO.2011.38.0261.

APA

Henry, N. L., Azzouz, F., Desta, Z., Li, L., Nguyen, A. T., Lemler, S., Hayden, J., Tarpinian, K., Yakim, E., Flockhart, D. A., Stearns, V., Hayes, D. F., & Storniolo, A. M. (2012). Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 30(9), 936–942. https://doi.org/10.1200/JCO.2011.38.0261

Chicago

Henry, N Lynn, Faouzi Azzouz, Zereunesay Desta, Lang Li, Anne T Nguyen, Suzanne Lemler, Jill Hayden, et al. 2012. “Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30 (9): 936–42. doi:10.1200/JCO.2011.38.0261.